Lifetime direct medical costs of treating type 2 diabetes and diabetic complications

American Journal of Preventive Medicine

Volumn 45, Issue 3, 2013, Pages 253-261

  Zhuo, Xiaohui ^a   Zhang, Ping ^a   Hoerger, Thomas J ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SIMULATION; DRUG COST; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; COMPUTER SIMULATION; COST OF ILLNESS; DELIVERY OF HEALTH CARE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; SEX FACTORS; UNITED STATES;

EID: 84882959753     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2013.04.017     Document Type: Article

References (51)

1. American Diabetes Association Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 4 2013 1033 1046
2. E.S. Huang, A. Basu, M.J. O'Grady, and J.C. Capretta Using clinical information to project federal health care spending Health Aff (Millwood) 28 5 2009 w978 990
3. American Diabetes Association Economic costs of diabetes in the U.S. in 2007 Diabetes Care 31 3 2008 596 615
4. Y. Chen, W.W. Quick, and W. Yang Cost of gestational diabetes mellitus in the U.S. in 2007 Popul Health Manag 12 3 2009 165 174
5. L. Ettaro, T.J. Songer, P. Zhang, and M.M. Engelgau Cost-of-illness studies in diabetes mellitus Pharmacoeconomics 22 3 2004 149 164
6. T.J. Songer Studies on the cost of diabetes Diabetes public health resource 1998 www.cdc.gov/diabetes/pubs/costs/intro.htm#references
7. CDC Diabetes Cost-effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 287 19 2002 2542 2551
8. T.J. Hoerger, J.E. Segel, P. Zhang, and S.W. Sorensen Validation of the CDC-RTI diabetes cost-effectiveness model Research Triangle Park NC: RTI International 2009
9. W.H. Herman, T.J. Hoerger, and M. Brandle The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance Ann Intern Med 142 5 2005 323 332
10. T.J. Hoerger, R. Harris, K.A. Hicks, K. Donahue, S. Sorensen, and M. Engelgau Screening for type 2 diabetes mellitus: a cost-effectiveness analysis Ann Intern Med 140 9 2004 689 699
11. X. Zhuo, P. Zhang, and E.W. Gregg A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years Health Aff (Millwood) 31 1 2012 50 60
12. National Center for Health Statistics National Health and Nutrition Examination Survey Data 2010 DHHS, CDC Hyattsville MD
13. M. Fowler Microvascular and macrovascular complications of diabetes Clin Diabetes 29 3 2011 6
14. M. Mitka Report quantifies diabetes complications JAMA 297 21 2007 2337 2338
15. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 7160 1998 703 713
16. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 24 2008 2545 2559
17. I.F. Gazi, and D.P. Mikhailidis Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp Diabetes Care 29 11 2006 2561 author reply 2561-2
18. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 2008 2560 2572
19. B. Hemmingsen, S.S. Lund, and C. Gluud Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials BMJ 343 2011 d6898
20. A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, and R.R. Holman Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 1 2003 225 232
21. T. Haak Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 9131 1998 837 853
22. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
23. R.J. Stevens, V. Kothari, A.I. Adler, and I.M. Stratton The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) Clin Sci (Lond) 101 6 2001 671 679
24. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 9131 1998 837 853
25. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 1 2009 193 203
26. E.W. Gregg, Q. Gu, Y.J. Cheng, K.M. Narayan, and C.C. Cowie Mortality trends in men and women with diabetes, 1971 to 2000 Ann Intern Med 147 3 2007 149 155
27. G.C. Alexander, N.L. Sehgal, R.M. Moloney, and R.S. Stafford National trends in treatment of type 2 diabetes mellitus, 1994-2007 Arch Intern Med 168 19 2008 2088 2094
28. Red book: pharmacy's fundamental reference, 2010 edition. New York: Thomson Reuters, 2010
29. National Center for Health Statistics National Health Interview Survey diabetes supplement 2006 NCHS Hyattsville MD
30. G.A. Nichols, S. Vupputuri, and H. Lau Medical care costs associated with progression of diabetic nephropathy Diabetes Care 34 11 2011 2374 2378
31. NIH, National Institute of Diabetes and Digestive and Kidney Diseases USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the U.S 2012 US Renal Data System Bethesda MD
32. J.A. O'Brien, A.R. Patrick, and J.J. Caro Cost of managing complications resulting from type 2 diabetes mellitus in Canada BMC Health Serv Res 3 1 2003 7
33. D.B. Rein, P. Zhang, and K.E. Wirth The economic burden of major adult visual disorders in the U.S Arch Ophthalmol 124 12 2006 1754 1760
34. T.N. Taylor, P.H. Davis, J.C. Torner, J. Holmes, J.W. Meyer, and M.F. Jacobson Lifetime cost of stroke in the U.S Stroke 27 9 1996 1459 1466
35. C. Hogan, J. Lunney, J. Gabel, and J. Lynn Medicare beneficiaries' costs of care in the last year of life Health Aff (Millwood) 20 4 2001 188 195
36. M. Brandle, H. Zhou, and B.R. Smith The direct medical cost of type 2 diabetes Diabetes Care 26 8 2003 2300 2304
37. J.J. Caro, A.J. Ward, and J.A. O'Brien Lifetime costs of complications resulting from type 2 diabetes in the U.S Diabetes Care 25 3 2002 476 481
38. H. Birnbaum, S. Leong, and A. Kabra Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence Womens Health Issues 13 6 2003 204 213
39. D.P. Goldman, Y. Zheng, and F. Girosi The benefits of risk factor prevention in Americans aged 51 years and older Am J Public Health 99 11 2009 2096 2101
40. CDC. National Diabetes Prevention Program. 2011 11/04/2011 [cited 2012 06/01/2012]. www.cdc.gov/diabetes/prevention/index.htm.
41. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 2002 393 403
42. X.R. Pan, G.W. Li, and Y.H. Hu Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study Diabetes Care 20 4 1997 537 544
43. J. Tuomilehto, J. Lindstrom, and J.G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 18 2001 1343 1350
44. M.K. Ali, J. Echouffo-Tcheugui, and D.F. Williamson How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Millwood) 31 1 2012 67 75
45. R. Li, P. Zhang, L.E. Barker, F.M. Chowdhury, and X. Zhang Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review Diabetes Care 33 8 2010 1872 1894
46. S. De Geest, and E. Sabate Adherence to long-term therapies: evidence for action Eur J Cardiovasc Nurs 2 4 2003 323
47. G.L. Beckles, M.M. Engelgau, K.M. Narayan, W.H. Herman, R.E. Aubert, and D.F. Williamson Population-based assessment of the level of care among adults with diabetes in the U.S Diabetes Care 21 9 1998 1432 1438
48. CDC. National diabetes fact sheet. 2011. www.cdc.gov/diabetes/pubs/pdf/ ndfs-2011.pdf.
49. R.J. Koopman, A.G. Mainous 3rd, V.A. Diaz, and M.E. Geesey Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000 Ann Fam Med 3 1 2005 60 63
50. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study Diabetes Care 21 12 1998 2180 2184
51. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 S1 2010 S11 61